Nov 20, 2019 – Astellas Pharma Inc. and Welldoc, Inc. announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions, BlueStar® in Japan and certain other Asian markets for patients with diabetes.
U.S. Food and Drug Administration (FDA)- in the United States cleared the use of BlueStar by healthcare providers and their patients aged 18 years and older who have type 1 or type 2 diabetes. It not only assists patients in managing their disease by capturing ,transmitting blood glucose data and tracking medication, activity, diet and exercise, but also useful for individual patient treatment data and machine learning to provide customized motivational, behavioral, and educational training messages to aid in diabetes self-management. https://www.astellas.com/en/news/15441
